Jain Global LLC Takes $6.27 Million Position in Sanofi $SNY

Jain Global LLC acquired a new position in shares of Sanofi (NASDAQ:SNY) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 132,836 shares of the company’s stock, valued at approximately $6,270,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC boosted its holdings in Sanofi by 52.6% in the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after acquiring an additional 1,869 shares during the last quarter. AQR Capital Management LLC raised its holdings in Sanofi by 107.2% during the 1st quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock worth $1,693,000 after purchasing an additional 15,791 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Sanofi by 1.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock worth $2,732,000 after purchasing an additional 752 shares during the period. Sivia Capital Partners LLC boosted its stake in shares of Sanofi by 5.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock valued at $326,000 after purchasing an additional 347 shares during the last quarter. Finally, Savant Capital LLC boosted its stake in shares of Sanofi by 17.1% in the 2nd quarter. Savant Capital LLC now owns 8,423 shares of the company’s stock valued at $407,000 after purchasing an additional 1,227 shares during the last quarter. 14.03% of the stock is owned by institutional investors and hedge funds.

Sanofi Stock Up 0.9%

Shares of NASDAQ SNY opened at $43.98 on Tuesday. The company has a quick ratio of 0.73, a current ratio of 1.09 and a debt-to-equity ratio of 0.20. The firm has a market cap of $107.27 billion, a PE ratio of 12.22, a P/E/G ratio of 1.13 and a beta of 0.45. The company’s fifty day simple moving average is $46.78 and its 200 day simple moving average is $48.17. Sanofi has a 12-month low of $43.34 and a 12-month high of $59.17.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a research note on Monday, December 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Sanofi in a research report on Monday, December 29th. Barclays downgraded Sanofi from an “overweight” rating to an “equal weight” rating in a report on Tuesday, January 6th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Sanofi in a research note on Friday, January 16th. Finally, Citigroup assumed coverage on Sanofi in a research report on Tuesday, January 27th. They set a “neutral” rating on the stock. Five research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Sanofi presently has a consensus rating of “Hold” and a consensus target price of $62.67.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.